View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Benefits of FDA Third-Party Review Programmes

It is indisputable that third-party review can speed the time to market for a 510(k) and prevent RTA. On the other hand, does the money need to be spent?

Does the time to market matter? Are you sure enough of your 510(k) competence that you are equally sure FDA will accept your filing? Did you do, or have you planned a pre-sub with FDA? Does your submission even qualify for third party review?

These are all important questions to ask yourself, and each should be addressed at the earliest possible stages of medical device development.

This paper introduces the reader to the Accredited Persons Programme and provides insight into the various considerations in making a cost/benefit decision with regard to utilization of the programme.

Click here to read more.

Clinical trial consulting and pharmaceutical consulting professionals will benefit by becoming current on adaptive trial design.
Safety surveillance and pharmacovigilance consulting to generic drug manufacturers, as well as generic drug labelling consulting may soon become a service in demand.
Pharmaceutical Development Group (PDG) is a drug and medical device consultant that continuously engages in meetings and interactions with the US Food and Drug Administration...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology